# A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

> **NCT06304961** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 46 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** Tozorakimab

## Key facts

- **NCT ID:** NCT06304961
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304961, "A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06304961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*